Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?
NCT ID: NCT07069933
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
50 participants
INTERVENTIONAL
2025-07-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
NCT01839240
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00061945
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
NCT00003405
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02666950
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
NCT01260714
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control arm
Standard Care
Chemotherapy
Standard Care (in control arm)
Interventional arm
Standard Care plus itraconazole
Standard care +itraconazole 200mg
Is an antifungal used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard care +itraconazole 200mg
Is an antifungal used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals.
Chemotherapy
Standard Care (in control arm)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients whose ECOG performance status ranged from 0-2 and are fit for all treatments protocols
Exclusion Criteria
2. Patients with history alcohol intake, acute or chronic.
3. Patients with documented hypersensitivity or allergy to Itraconazole.
4. Patients suffer from chronic heart failure
5. Patients present with severe dehydration.
6. Patients with severe kidney dysfunction
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noha Mansour
Lecturer of Clinical Pharmacy and Pharmacy Practice
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed el-Husseiny shams
Role: PRINCIPAL_INVESTIGATOR
Professor Department of Clinical pharmacy and Pharmacy practice, Faculty of Pharmacy, Mansoura University
Moetaza Mahmoud Hassab Soliman
Role: STUDY_DIRECTOR
Associate professor of Clinical Pharmacy, Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University
Noha Osama Mansour Mansour
Role: STUDY_DIRECTOR
Lecturer of Clinical Pharmacy, Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University
Sara Mohamed Ali Atwa
Role: STUDY_DIRECTOR
Lecturer of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Oncology and Nuclear Medicine of Mansoura University Hospital, Mansoura,
Al Mansurah, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-42-2024-120
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.